DiaMedica Therapeutics (DMAC) Non Operating Interest Expenses (2024 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Non Operating Interest Expenses came in at $23000.0 in Q1 2026, up 2200.0% on a YoY basis from $1000.0 in Q1 2025, and up 2200.0% quarter-over-quarter from $1000.0 in Q1 2025.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Non Operating Interest Expenses (2024 - 2026) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Non Operating Interest Expenses for 3 consecutive years, with $23000.0 the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 20.27 Mn |
| 10 | DiaMedica Therapeutics | 364.00 Mn | 364.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 23,000.00 |
| Mar 31, 2025 | 1,000.00 |
| Mar 31, 2024 | 19,000.00 |